title: Severe thrombocytopenia related to long-term trastuzumab exposure.
abstract: Drug-induced immune thrombocytopenia may occur secondary to several chemotherapeutic agents or new targeted monoclonal antibodies, but thrombocytopenia induced by trastuzumab is a very rare occurrence. We report a case of severe thrombocytopenia related to the administration of trastuzumab six months after the first exposure.
authors.affiliation: Department of Oncology, Hospital Arnau de Vilanova, Lérida, Spain. elenaaguirreortega@yahoo.es
authors.forename: Elena
authors.initials: E
authors.lastname: Aguirre
authors.forename: Teresa
authors.initials: T
authors.lastname: Taberner
authors.forename: Armando
authors.initials: A
authors.lastname: Luaña
authors.forename: Serafin
authors.initials: S
authors.lastname: Morales
authors.forename: Antonio
authors.initials: A
authors.lastname: Llombart
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage / Q000009:adverse effects* / Q000276:immunology; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects* / Q000276:immunology; D001943:Breast Neoplasms / Q000188:drug therapy; D005260:Female; D006801:Humans; D008875:Middle Aged; D058990:Molecular Targeted Therapy / Q000379:methods; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000276:immunology*; D013921:Thrombocytopenia / Q000139:chemically induced* / Q000276:immunology*; D013997:Time Factors; D000068878:Trastuzumab
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D018719:Erb-b2 Receptor Tyrosine Kinases; D000068878:Trastuzumab; C508053:ERBB2 protein, human